Alec Stranahan
Stock Analyst at Bank of America Securities
(4.57)
# 955
Out of 4,501 analysts
597
Total ratings
54.1%
Success rate
10.9%
Average return
Main Sectors:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Maintained: Buy | $47 | $32.68 | +43.82% | 23 | Jul 8, 2026 | |
| NVAX Novavax | Maintained: Sell | $8 | $9.33 | -14.26% | 41 | Jul 7, 2026 | |
| AGIO Agios Pharmaceuticals | Reiterated: Buy | $40 → $46 | $41.23 | +11.57% | 32 | Jul 7, 2026 | |
| TGTX TG Therapeutics | Reiterated: Sell | $17 → $20 | $57.12 | -64.99% | 37 | Jul 7, 2026 | |
| HCM HUTCHMED (China) | Reiterated: Buy | $20 → $17 | $11.07 | +53.57% | 22 | Jul 7, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Buy | $83 | $53.35 | +55.58% | 26 | Jul 7, 2026 | |
| MGTX MeiraGTx Holdings | Maintained: Buy | $16 → $19 | $13.39 | +41.90% | 16 | Jul 7, 2026 | |
| MRNA Moderna | Reiterated: Sell | $34 → $38 | $68.27 | -44.34% | 24 | Jul 7, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $185 → $212 | $186.88 | +13.44% | 35 | Jun 25, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Hold | $19 | $14.22 | +33.66% | 18 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $35 | $19.21 | +82.20% | 1 | Jun 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $1.93 | +211.69% | 15 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $16 | $18.53 | -13.65% | 25 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 | $3.01 | +99.34% | 17 | May 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $364 | $365.81 | -0.49% | 30 | May 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 | $9.68 | +75.62% | 17 | May 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $9 | $9.49 | -5.16% | 17 | May 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $34 | $27.88 | +21.95% | 8 | May 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $9.96 | +60.64% | 20 | May 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $83 → $87 | $75.24 | +15.63% | 18 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $14 | $13.95 | +0.36% | 27 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $17 | $15.85 | +7.26% | 18 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 | $3.56 | +68.54% | 22 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $3.85 | +81.82% | 12 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 → $21 | $16.40 | +28.05% | 21 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $3.26 | - | 9 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $1.61 | - | 15 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 → $19 | $6.25 | +204.00% | 5 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $1 | $0.8175 | +22.32% | 13 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Sell | $800 → $565 | $664.52 | n/a | 3 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $1,150 → $1,100 | $1,188.58 | n/a | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $5 | $28.53 | n/a | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $10 → $1 | $1.97 | n/a | 4 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $35 | $3.18 | n/a | 1 | Jan 15, 2021 |
Beam Therapeutics
Jul 8, 2026
Maintained: Buy
Price Target: $47
Current: $32.68
Upside: +43.82%
Novavax
Jul 7, 2026
Maintained: Sell
Price Target: $8
Current: $9.33
Upside: -14.26%
Agios Pharmaceuticals
Jul 7, 2026
Reiterated: Buy
Price Target: $40 → $46
Current: $41.23
Upside: +11.57%
TG Therapeutics
Jul 7, 2026
Reiterated: Sell
Price Target: $17 → $20
Current: $57.12
Upside: -64.99%
HUTCHMED (China)
Jul 7, 2026
Reiterated: Buy
Price Target: $20 → $17
Current: $11.07
Upside: +53.57%
CRISPR Therapeutics AG
Jul 7, 2026
Maintained: Buy
Price Target: $83
Current: $53.35
Upside: +55.58%
MeiraGTx Holdings
Jul 7, 2026
Maintained: Buy
Price Target: $16 → $19
Current: $13.39
Upside: +41.90%
Moderna
Jul 7, 2026
Reiterated: Sell
Price Target: $34 → $38
Current: $68.27
Upside: -44.34%
Revolution Medicines
Jun 25, 2026
Reiterated: Buy
Price Target: $185 → $212
Current: $186.88
Upside: +13.44%
Intellia Therapeutics
Jun 15, 2026
Maintained: Hold
Price Target: $19
Current: $14.22
Upside: +33.66%
Jun 12, 2026
Initiated Coverage: Buy
Price Target: $35
Current: $19.21
Upside: +82.20%
Jun 11, 2026
Maintained: Buy
Price Target: $6
Current: $1.93
Upside: +211.69%
Jun 8, 2026
Maintained: Hold
Price Target: $16
Current: $18.53
Upside: -13.65%
May 31, 2026
Maintained: Hold
Price Target: $6
Current: $3.01
Upside: +99.34%
May 31, 2026
Maintained: Buy
Price Target: $364
Current: $365.81
Upside: -0.49%
May 31, 2026
Maintained: Buy
Price Target: $17
Current: $9.68
Upside: +75.62%
May 31, 2026
Maintained: Hold
Price Target: $9
Current: $9.49
Upside: -5.16%
May 31, 2026
Maintained: Buy
Price Target: $34
Current: $27.88
Upside: +21.95%
May 29, 2026
Maintained: Buy
Price Target: $16
Current: $9.96
Upside: +60.64%
May 26, 2026
Maintained: Buy
Price Target: $83 → $87
Current: $75.24
Upside: +15.63%
May 14, 2026
Reiterated: Buy
Price Target: $25 → $14
Current: $13.95
Upside: +0.36%
May 13, 2026
Maintained: Hold
Price Target: $17
Current: $15.85
Upside: +7.26%
May 13, 2026
Maintained: Hold
Price Target: $6
Current: $3.56
Upside: +68.54%
May 12, 2026
Reiterated: Buy
Price Target: $7
Current: $3.85
Upside: +81.82%
May 8, 2026
Reiterated: Buy
Price Target: $24 → $21
Current: $16.40
Upside: +28.05%
May 7, 2026
Maintained: Sell
Price Target: n/a
Current: $3.26
Upside: -
Apr 30, 2026
Maintained: Sell
Price Target: n/a
Current: $1.61
Upside: -
Apr 28, 2026
Maintained: Buy
Price Target: $21 → $19
Current: $6.25
Upside: +204.00%
Mar 27, 2026
Reiterated: Sell
Price Target: $1
Current: $0.8175
Upside: +22.32%
Dec 10, 2024
Initiated Coverage: Sell
Price Target: $800 → $565
Current: $664.52
Upside: n/a
Nov 1, 2024
Rated: Buy
Price Target: $1,150 → $1,100
Current: $1,188.58
Upside: n/a
Aug 15, 2023
Reiterated: Buy
Price Target: $6 → $5
Current: $28.53
Upside: n/a
Dec 2, 2022
Maintained: Sell
Price Target: $10 → $1
Current: $1.97
Upside: n/a
Jan 15, 2021
Downgraded: Hold
Price Target: $35
Current: $3.18
Upside: n/a